

Table 2. Summary of Natural History Study Mechanistic Samples for Participants over Baseline & Follow-up (Complete Collection/Visit Hx Required\*). Subjects that Develop T1D at some point during P2 or P3 are Excluded.  
 P2 (n=900); P3:6m (n=420); P3:12m (n=247); P3:18m (n=137) P3:24m (n=74); P3:30m (n=39); P3:36m (n=6)

Collection Phase*	Sample Type**	No. Subjects (% Row Total): <25%	No. Subjects (% Row Total): 25-50%	No. Subjects (% Row Total): >=25%	No. Subjects (% Row Total): >=50%	Risk Missing or TBD	Total No. Subjects Submitting Sample
Baseline	DNA	214 (40.5)	25 (4.7)	40 (7.6)	196 (37.1)	53 (10.0)	528
	HLA	368 (41.9)	27 (3.1)	77 (8.8)	293 (33.4)	113 (12.9)	878
	RNA	172 (41.2)	20 (4.8)	34 (8.2)	144 (34.5)	47 (11.3)	417
	PLASMA	171 (42.0)	20 (4.9)	32 (7.9)	140 (34.4)	44 (10.8)	407
	SERUM	171 (41.9)	20 (4.9)	34 (8.3)	139 (34.1)	44 (10.8)	408
	PBMC	168 (41.4)	20 (4.9)	34 (8.4)	140 (34.5)	44 (10.8)	406
Follow-up (6m)	RNA	85 (39.5)	18 (8.4)	18 (8.4)	84 (39.1)	10 (4.7)	215
	PLASMA	82 (38.9)	18 (8.5)	18 (8.5)	83 (39.3)	10 (4.7)	211
	SERUM	84 (39.4)	18 (8.5)	18 (8.5)	83 (39.0)	10 (4.7)	213
	PBMC	82 (38.9)	18 (8.5)	18 (8.5)	83 (39.3)	10 (4.7)	211
Follow-up (12m)	RNA	59 (39.6)	14 (9.4)	9 (6.0)	59 (39.6)	8 (5.4)	149
	PLASMA	59 (40.1)	14 (9.5)	9 (6.1)	57 (38.8)	8 (5.4)	147
	SERUM	58 (39.5)	14 (9.5)	9 (6.1)	58 (39.5)	8 (5.4)	147
	PBMC	60 (40.0)	14 (9.3)	9 (6.0)	59 (39.3)	8 (5.3)	150
Follow-up (18m)	RNA	38 (38.8)	9 (9.2)	1 (1.0)	47 (48.0)	3 (3.1)	98
	PLASMA	38 (39.6)	9 (9.4)	1 (1.0)	45 (46.9)	3 (3.1)	96
	SERUM	37 (38.9)	9 (9.5)	1 (1.1)	45 (47.4)	3 (3.2)	95
	PBMC	38 (38.8)	9 (9.2)	1 (1.0)	47 (48.0)	3 (3.1)	98
Follow-up (24m)	RNA	24 (42.9)	3 (5.4)	1 (1.8)	27 (48.2)	1 (1.8)	56
	PLASMA	24 (42.9)	3 (5.4)	1 (1.8)	27 (48.2)	1 (1.8)	56
	SERUM	24 (42.9)	3 (5.4)	1 (1.8)	27 (48.2)	1 (1.8)	56
	PBMC	24 (42.9)	3 (5.4)	1 (1.8)	27 (48.2)	1 (1.8)	56
Follow-up (30m)	RNA	12 (36.4)	2 (6.1)	1 (3.0)	16 (48.5)	2 (6.1)	33
	PLASMA	13 (38.2)	2 (5.9)	1 (2.9)	16 (47.1)	2 (5.9)	34
	SERUM	13 (38.2)	2 (5.9)	1 (2.9)	16 (47.1)	2 (5.9)	34
	PBMC	13 (38.2)	2 (5.9)	1 (2.9)	16 (47.1)	2 (5.9)	34
Follow-up (36m)	RNA	2 (33.3)	. (.)	. (.)	3 (50.0)	1 (16.7)	6
	PLASMA	2 (33.3)	. (.)	. (.)	3 (50.0)	1 (16.7)	6
	SERUM	2 (33.3)	. (.)	. (.)	3 (50.0)	1 (16.7)	6
	PBMC	2 (33.3)	. (.)	. (.)	3 (50.0)	1 (16.7)	6

\* A subject enumerated in any Phase 3 visit is required to have had a Baseline (Phase 2) visit, as well as have completed "all" P3 visits preceding their latest P3 visit.

\*\* All DNA samples collected -- across all visits herein (Baseline and any Phase 3 follow-up) -- are presented at Baseline. Note that a subject should have only provided one DNA sample, although it is possible multiple were provided.